. "Ribavirine"@en . . . . "9.5 hours"@en . . . . . . . . . . . . . . . . . . . . . . . " "@en . . . . "For the treatment of chronic hepatitis C and for respiratory syncytial virus (RSV)."@en . . . . . . . . . . . . . . . . . . . "approved"@en . . . . . . . . . . . "36791-04-5"@en . . . . . "Side effects include \"flu-like\" symptoms, such as headache, fatigue, myalgia, and fever. The LD₅₀ in mice is 2 g/kg orally and is associated with hypoactivity and gastrointestinal symptoms (estimated human equivalent dose of 0.17 g/kg, based on body surface area conversion)."@en . . . "* Apparent cl=26 L/h [A single oral dose]"@en . "RBV"@en . . "\"DrugSyn.org\":http://www.drugsyn.org/Ribavirin.htm"@en . . "# Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF: In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 2005 Oct;68(1):10-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16087250 # Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK: Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(50):705-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/4340949 # Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS: Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006 Oct;13(10):683-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16970600 # Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C: Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16123681"@en . . . . "Tribavirin"@en . . . . . . . . . . . . . . . . . . . . . "Ribavirin"@en . "Ribavirina"@en . . "A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. [PubChem]"@en . . . . . . . . . . "Ribavirinum"@en . "1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide"@en . . . "1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide"@en . . "Ribavirin"@en . . . . "Hepatitis C virus, RSV and other RNA/DNA viruses"@en . "Ribavirin is readily phosphorylated intracellularly by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is a potent competitive inhibitor of inosine monophosphate (IMP) dehydrogenase, viral RNA polymerase and messenger RNA (mRNA) guanylyltransferase (viral) and can be incorporated into RNA in RNA viral species.. Guanylyltranserase inhibition stops the capping of mRNA. These diverse effects result in a marked reduction of intracellular guanosine triphosphate (GTP) pools and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome causing lethal mutagenesis and a subsequent decrease in specific viral infectivity."@en . . . . . . "Rapidly and extensively absorbed following oral administration. However, due to first-pass metabolism, the absolute bioavailability averages 64%."@en . . .